S

Shanghai Henlius Biotech Inc
HKEX:2696

Watchlist Manager
Shanghai Henlius Biotech Inc
HKEX:2696
Watchlist
Price: 20.25 HKD -1.94% Market Closed
Market Cap: 11B HKD
Have any thoughts about
Shanghai Henlius Biotech Inc?
Write Note

Intrinsic Value

The intrinsic value of one Shanghai Henlius Biotech Inc stock under the Base Case scenario is 24.65 HKD. Compared to the current market price of 20.25 HKD, Shanghai Henlius Biotech Inc is Undervalued by 18%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
24.65 HKD
Undervaluation 18%
Intrinsic Value
Price
S
Worst Case
Base Case
Best Case

Valuation Backtest
Shanghai Henlius Biotech Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for Shanghai Henlius Biotech Inc cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about Shanghai Henlius Biotech Inc?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Shanghai Henlius Biotech Inc

Provide an overview of the primary business activities
of Shanghai Henlius Biotech Inc.

What unique competitive advantages
does Shanghai Henlius Biotech Inc hold over its rivals?

What risks and challenges
does Shanghai Henlius Biotech Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Shanghai Henlius Biotech Inc.

Provide P/S
for Shanghai Henlius Biotech Inc.

Provide P/E
for Shanghai Henlius Biotech Inc.

Provide P/OCF
for Shanghai Henlius Biotech Inc.

Provide P/FCFE
for Shanghai Henlius Biotech Inc.

Provide P/B
for Shanghai Henlius Biotech Inc.

Provide EV/S
for Shanghai Henlius Biotech Inc.

Provide EV/GP
for Shanghai Henlius Biotech Inc.

Provide EV/EBITDA
for Shanghai Henlius Biotech Inc.

Provide EV/EBIT
for Shanghai Henlius Biotech Inc.

Provide EV/OCF
for Shanghai Henlius Biotech Inc.

Provide EV/FCFF
for Shanghai Henlius Biotech Inc.

Provide EV/IC
for Shanghai Henlius Biotech Inc.

Show me price targets
for Shanghai Henlius Biotech Inc made by professional analysts.

What are the Revenue projections
for Shanghai Henlius Biotech Inc?

How accurate were the past Revenue estimates
for Shanghai Henlius Biotech Inc?

What are the Net Income projections
for Shanghai Henlius Biotech Inc?

How accurate were the past Net Income estimates
for Shanghai Henlius Biotech Inc?

What are the EPS projections
for Shanghai Henlius Biotech Inc?

How accurate were the past EPS estimates
for Shanghai Henlius Biotech Inc?

What are the EBIT projections
for Shanghai Henlius Biotech Inc?

How accurate were the past EBIT estimates
for Shanghai Henlius Biotech Inc?

Compare the revenue forecasts
for Shanghai Henlius Biotech Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Shanghai Henlius Biotech Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Shanghai Henlius Biotech Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Shanghai Henlius Biotech Inc compared to its peers.

Compare the P/E ratios
of Shanghai Henlius Biotech Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Shanghai Henlius Biotech Inc with its peers.

Analyze the financial leverage
of Shanghai Henlius Biotech Inc compared to its main competitors.

Show all profitability ratios
for Shanghai Henlius Biotech Inc.

Provide ROE
for Shanghai Henlius Biotech Inc.

Provide ROA
for Shanghai Henlius Biotech Inc.

Provide ROIC
for Shanghai Henlius Biotech Inc.

Provide ROCE
for Shanghai Henlius Biotech Inc.

Provide Gross Margin
for Shanghai Henlius Biotech Inc.

Provide Operating Margin
for Shanghai Henlius Biotech Inc.

Provide Net Margin
for Shanghai Henlius Biotech Inc.

Provide FCF Margin
for Shanghai Henlius Biotech Inc.

Show all solvency ratios
for Shanghai Henlius Biotech Inc.

Provide D/E Ratio
for Shanghai Henlius Biotech Inc.

Provide D/A Ratio
for Shanghai Henlius Biotech Inc.

Provide Interest Coverage Ratio
for Shanghai Henlius Biotech Inc.

Provide Altman Z-Score Ratio
for Shanghai Henlius Biotech Inc.

Provide Quick Ratio
for Shanghai Henlius Biotech Inc.

Provide Current Ratio
for Shanghai Henlius Biotech Inc.

Provide Cash Ratio
for Shanghai Henlius Biotech Inc.

What is the historical Revenue growth
over the last 5 years for Shanghai Henlius Biotech Inc?

What is the historical Net Income growth
over the last 5 years for Shanghai Henlius Biotech Inc?

What is the current Free Cash Flow
of Shanghai Henlius Biotech Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Shanghai Henlius Biotech Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Shanghai Henlius Biotech Inc

Current Assets 2.4B
Cash & Short-Term Investments 649.4m
Receivables 788.9m
Other Current Assets 958.3m
Non-Current Assets 7.6B
PP&E 2.7B
Intangibles 4.8B
Other Non-Current Assets 46.4m
Current Liabilities 4.9B
Accounts Payable 617.1m
Other Current Liabilities 4.3B
Non-Current Liabilities 2.5B
Long-Term Debt 1.2B
Other Non-Current Liabilities 1.3B
Efficiency

Earnings Waterfall
Shanghai Henlius Biotech Inc

Revenue
5.6B CNY
Cost of Revenue
-1.5B CNY
Gross Profit
4.1B CNY
Operating Expenses
-3.3B CNY
Operating Income
840.6m CNY
Other Expenses
-148.3m CNY
Net Income
692.3m CNY

Free Cash Flow Analysis
Shanghai Henlius Biotech Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

Shanghai Henlius Biotech Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
ROE is Increasing
ROIC is Increasing
47/100
Profitability
Score

Shanghai Henlius Biotech Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Shanghai Henlius Biotech Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Positive Net Debt
Low Altman Z-Score
43/100
Solvency
Score

Shanghai Henlius Biotech Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Shanghai Henlius Biotech Inc

Wall Street analysts forecast Shanghai Henlius Biotech Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Shanghai Henlius Biotech Inc is 22.91 HKD with a low forecast of 20.53 HKD and a high forecast of 25.83 HKD.

Lowest
Price Target
20.53 HKD
1% Upside
Average
Price Target
22.91 HKD
13% Upside
Highest
Price Target
25.83 HKD
28% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Shanghai Henlius Biotech Inc?

Click here to dive deeper.

Dividends

Shanghai Henlius Biotech Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for Shanghai Henlius Biotech Inc is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Shanghai Henlius Biotech Inc

Country

China

Industry

Biotechnology

Market Cap

11B HKD

Dividend Yield

0%

Description

Shanghai Henlius Biotech, Inc. engages in the development and production of monoclonal antibody drugs. The company is headquartered in Shanghai, Shanghai and currently employs 2,234 full-time employees. The company went IPO on 2019-09-25. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The firm is also engaged in the provision of related technical services. The firm operates its businesses primarily in Mainland China and the United States.

Contact

SHANGHAI
Shanghai
9F, Innov Tower, Capitaland Building, 1801 Hongmei Road, Xuhui District
www.henlius.com

IPO

2019-09-25

Employees

2 234

Officers

Executive Chairman of the Board
Mr. Wenjie Zhang
CEO & Executive Director
Dr. Jun Zhu
President
Ms. Huang Wei
Co-founder & Head of Strategy Advisory Committee
Dr. Shi-Kau Liu
Co-Founder & Co-Head of Innovative Advisory Committee
Dr. Wei-Dong Jiang
VP & CFO
Mr. Yingbo Mao
Show More
CTO & Senior VP
Dr. Jifeng Zhang
Vice President of Legal & Compliance Department
Ms. Miaojie Chen
Deputy GM of Public Relations & Joint Company Secretary
Ms. Yan Wang
VP of Sales & Oncology Business Unit
Mr. Wallis Zeng
Show Less

See Also

Discover More
What is the Intrinsic Value of one Shanghai Henlius Biotech Inc stock?

The intrinsic value of one Shanghai Henlius Biotech Inc stock under the Base Case scenario is 24.65 HKD.

Is Shanghai Henlius Biotech Inc stock undervalued or overvalued?

Compared to the current market price of 20.25 HKD, Shanghai Henlius Biotech Inc is Undervalued by 18%.

Back to Top